Cargando…
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
Mucopolysaccharidosis type I (MPS I) is a lysosomal disease, caused by a deficiency of the enzyme alpha-L-iduronidase (IDUA). IDUA catalyzes the degradation of the glycosaminoglycans dermatan and heparan sulfate (DS and HS, respectively). Lack of the enzyme leads to pathologic accumulation of undegr...
Autores principales: | Hampe, Christiane S., Wesley, Jacob, Lund, Troy C., Orchard, Paul J., Polgreen, Lynda E., Eisengart, Julie B., McLoon, Linda K., Cureoglu, Sebahattin, Schachern, Patricia, McIvor, R. Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911293/ https://www.ncbi.nlm.nih.gov/pubmed/33572941 http://dx.doi.org/10.3390/biom11020189 |
Ejemplares similares
-
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology
por: Hampe, Christiane S., et al.
Publicado: (2020) -
Differences in MPS I and MPS II Disease Manifestations
por: Hampe, Christiane S., et al.
Publicado: (2021) -
Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I
por: Lund, Troy C., et al.
Publicado: (2020) -
Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H
por: Raymond, Gerald V., et al.
Publicado: (2016) -
Bilateral glomus tympanicum tumors: Human temporalbone study
por: Fukushima, Hisaki, et al.
Publicado: (2018)